By Lance Duroni ( January 12, 2012, 3:50 PM EST) -- An Inhibitex Inc. shareholder launched a class action in Delaware state court on Wednesday challenging Bristol-Myers Squibb Co.'s $2.5 billion bid to acquire the biopharmaceutical company and its clinical-stage hepatitis C drug, despite the offer's hefty premium....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.